Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone-Reference-Cited by-同舟云学术

Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone

Published:2019-12-10 Issue:23 Volume:3 Page:4095-4103
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Kastritis Efstathios¹^ORCID,Roussou Maria¹,Gavriatopoulou Maria¹,Kanellias Nikolaos¹,Migkou Magdalini¹,Eleutherakis-Papaiakovou Evangelos¹^ORCID,Ziogas Dimitrios C.¹^ORCID,Fotiou Despina¹,Ntanasis-Stathopoulos Ioannis¹^ORCID,Dialoupi Ioanna¹,Giannouli Stavroula²,Tsirigotis Panagiotis³,Delimpasi Sossana⁴,Mparmparousi Despina⁵,Spyropoulou-Vlachou Mairylin⁶,Xirokosta Aikaterini⁵,Terpos Evangelos¹^ORCID,Dimopoulos Meletios A.¹^ORCID

Affiliation:

1. Department of Clinical Therapeutics,

2. Second Department of Internal Medicine, and

3. Second Department of Internal Medicine, Propaedeutic, ''ATTIKON'' General University Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece;

4. Department of Haematology, Evangelismos Hospital, Athens, Greece; and

5. Haematology Laboratory and

6. Immunology Laboratory, Alexandra Hospital, Athens, Greece

Abstract

Key Points There was no significant difference in response rates, PFS, or OS among patients that developed resistance to different lenalidomide doses. Longer duration of prior lenalidomide and a longer lenalidomide-free interval are associated with better outcomes with pomalidomide.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/3/23/4095/1547217/advancesadv2019000539.pdf

Reference40 articles.

1. The genetic architecture of multiple myeloma;Morgan;Nat Rev Cancer,2012

2. Clonal competition with alternating dominance in multiple myeloma;Keats;Blood,2012

3. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma;Melchor;Leukemia,2014

4. Evolutionary biology of high-risk multiple myeloma;Pawlyn;Nat Rev Cancer,2017

5. Multiple myeloma clonal evolution in homogeneously treated patients;Corre;Leukemia,2018

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece;Clinical Lymphoma Myeloma and Leukemia;2024-07

2. Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide;Blood Cancer Journal;2024-03-26

3. An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study);Future Oncology;2024-02-29

4. Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study.;Haematologica;2024-01-18

5. IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?;Life;2023-11-20